Neoadjuvant pembrolizumab extended event-free survival compared with adjuvant-only administration of the anti-PD-1 therapy among patients with resectable melanoma, according to phase 2 study results presented at ESMO Congress.
2022
Study: Fianlimab With Cemiplimab Combination Shows High Response Rate in Certain Patients With Advanced Melanoma
New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.
Acral lentiginous melanoma: 8 questions about this rare skin cancer
Many skin cancers — including cutaneous melanoma — are associated with UV exposure. Yet acral lentiginous melanoma develops only on areas of the body that can’t really be protected by sunscreen — and there’s no direct link to UV exposure.
Test May Predict Recurrence and Response to Immunotherapy in Melanoma Patients
Scientists at the Perlmutter Cancer Center in the NYU Grossman School of Medicine have developed an experimental test based on a composite panel of autoantibody signatures that generates a score that can be used to predict the occurrence of severe side effects or the recurrence of cancer in melanoma patients who have received immune checkpoint blockade immunotherapies—a therapeutic modality that bolsters the patients own immune system to attack malignant cells.